Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • TPG-Manipal enter into...

    TPG-Manipal enter into Exclusive talks to Acquire Medanta- Report

    GarimaWritten by Garima Published On 2019-02-17T10:05:56+05:30  |  Updated On 13 Aug 2021 4:40 PM IST

    Mumbai: After losing out on the Fortis deal, the Manipal Group backed by TPG is making moves toward acquiring Gurugram Based Medanta Medicity by entering into exclusive negotiations with founder Dr Naresh Trehan and other investors


    Medical Dialogues team had earlier reported that that last year TPG-Manipal began to buy a majority stake in the Gurugram-based super-speciality hospital Medanta-The Medicity.

    The Manipal Hospital backed up by its investors TPG Capital and Temasek heading closer to acquire Medanta Hospitals had set at a valuation of Rs 5800-6000 crore


    Medanta, founded in 2009, operates super speciality hospitals and clinics across cities including Gurgaon, Lucknow, Indore, Ranchi and Sri Ganganagar. Founded by renowned cardiac surgeon Dr Naresh Trehan, Trehan and his family, along with co-founder Sunil Sachdeva own 55% of the share. US-based private equity fund Carlyle Group owns 27% in Medanta, while Singapore's Temasek Holdings Pte holds a share of 18%.


    In 2013, Carlyle had acquired a 27% stake in Global Health Pvt. Ltd, which owns, manages and operates Medanta, while Temasek bought its 18% stake in Global Health in 2015 from Punj Lloyd Ltd.


    Also Read: Manipal Hospitals closes in to acquire Medanta stake at enterprise valuation 6000 crore


    Livemint now reports that private equity firm TPG Capital and Manipal Group have together entered into exclusive negotiation with founder Dr Naresh Trehan and other investors to buy a controlling stake in hospital operator Medanta. With this Medanta will be unable to join hands with any other buyer for a period of three months.


    Presently the prospective buyers are reported to be conducting a legal binding process evaluating the company's assets.


    Confirmation to the same was given to live mint by two people aware of the development, requesting anonymity.


    "The TPG-Manipal combine is in advanced stages of negotiations and they recently entered into exclusive talks. They are currently conducting due diligence on the asset. They have a three-month exclusivity period, so Medanta will not be talking to any other buyer during this period," the first person cited above told the daily.


    However, neither Medanta nor TPG Capital commented on the sales processes.


    According to earlier media reports, TPG had been actively looking to build up Asia Healthcare Holdings—its healthcare platform and Medanta's acquisition would help the private equity firm diversify its healthcare investments.TPG Capital has sharpened its focus on healthcare investments in India since 2016.


    In 2018, TPG was in a race to acquire the country's second largest healthcare provider, Fortis Healthcare. The deal was finally settled by IHH Healthcare, which offered to invest Rs 4,000 crore in the hospital chain.TPG's healthcare portfolio in India includes Cancer Treatment Services International, Bengaluru-based Rhea Healthcare Pvt. Ltd, an operator of hospitals for women and children under 'Motherhood' brand; and Sai Life Sciences, drug discovery and manufacturing firm.


    Also Read: Fortis Acquisition boils down to TPG verus IHH


    According to recent media reports, Medanta has been under pressure because of price controls imposed by National Pharmaceutical Pricing Authority (NPPA).

    In August 2017, the drug pricing regulator capped the prices of knee implants, reducing product prices by as much as 70% and had brought cardiac stents under price control in February to make them affordable. The price of drug-eluting stents drastically went down to about Rs 30,000 from over Rs 2 lakh, which evidently hit the revenues of all the hospitals in the country.

    Similarly, Medanta also saw a cry off in its revenue after several of its top doctors quit to join rivals such as Fortis and Max Healthcare Ltd.
    CarlyledealDr Naresh TrehanFortisFortis HealthcareGlobal HealthHealthcarehospitalHospital news in IndiaInvestmentManipal Health Enterprises Pvt LtdManipal hospitalManipal Hospital GroupMedantaMedanta Hospitalmemgsharestakesurgeon naTemasekTPGTPG capitalvaluation
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok